共 85 条
Progressive Staging of Pilot Studies to Improve Phase III Trials for Motor Interventions
被引:155
作者:
Dobkin, Bruce H.
[1
]
机构:
[1] Univ Calif Los Angeles, Dept Neurol, Geffen Sch Med, Los Angeles, CA 90095 USA
关键词:
Stroke rehabilitation;
Spinal cord injury;
Motor control;
Clinical trials;
Robotics;
Treadmill training;
WEIGHT-SUPPORTED TREADMILL;
INDUCED MOVEMENT THERAPY;
SPINAL-CORD-INJURY;
TRANSCRANIAL MAGNETIC STIMULATION;
STROKE REHABILITATION ASSESSMENT;
CLINICALLY IMPORTANT DIFFERENCE;
UPPER EXTREMITY FUNCTION;
RANDOMIZED-TRIAL;
EXCITE TRIAL;
ARM FUNCTION;
D O I:
10.1177/1545968309331863
中图分类号:
R74 [神经病学与精神病学];
学科分类号:
摘要:
Based on the suboptimal research pathways that finally led to multicenter randomized clinical trials (MRCTs) of treadmill training with partial body weight support and of robotic assistive devices, strategically planned successive stages are proposed for pilot studies of novel rehabilitation interventions. Stage 1, consideration-of-concept studies, drawn from animal experiments, theories, and observations, delineate the experimental intervention in a small convenience sample of participants, so the results must be interpreted with caution. Stage 2, development-of-concept pilots, should optimize the components of the intervention, settle on most appropriate outcome measures, and examine dose-response effects. A well-designed study that reveals no efficacy should be published to counterweight the confirmation bias of positive trials. Stage 3, demonstration-of-concept pilots, can build out from what has been learned to test at least 15 participants in each arm, using random assignment and blinded outcome measures. A control group should receive an active practice intervention aimed at the same primary outcome. A third arm could receive a substantially larger dose of the experimental therapy or a combinational intervention. If only 1 site performed this trial, a different investigative group should aim to reproduce positive outcomes based on the optimal dose of motor training. Stage 3 studies ought to suggest an effect size of 0.4 or higher, so that approximately 50 participants in each arm will be the number required to test for efficacy in a stage 4, proof-of-concept MRCT. By developing a consensus around acceptable and necessary practices for each stage, similar to CONSORT recommendations for the publication of phase III clinical trials, better quality pilot studies may move quickly into better designed and more successful MRCTs of experimental interventions.
引用
收藏
页码:197 / 206
页数:10
相关论文